## REMARKS

Claims 1 and 4 have been amended to recite that the transition metal complex classified into Class C is selected from the group consisting of the specific iridium complexes disclosed at page 18, lines 17-20, and page 19, lines 9-12 in the present application. Claims 3, 5, and 8 have been canceled.

Entry of the above amendment is respectfully requested.

Preliminarily, Applicants thank the Examiner for the personal interview held with their representative on September 13, 2005. Applicants believe that the interview materially advanced the prosecution of the present case.

## Rejection of Claims 1-11 under 35 U.S.C. § 103 (a)

The Examiner has rejected Claims 1-11 under 35 U.S.C. § 103(a) as allegedly being obvious over U.S. Patent No. 5,783,373 to Mydlarz, *et al.* ("Mydlarz '373") or U.S. Patent No. 5,783,378 to Mydlarz, *et al.* ("Mydlarz '378"), in view of Edwards '601.

In response to this rejection, Applicants note initially that independent claims 1 and 4 have been amended to recite that the transition metal complex classified into Class C is selected from a specific group of iridium complexes. Applicants submit that these specific iridium complexes are not included in the exemplified dopants in the Mydlarz patents as cited by the Examiner, and are not taught or suggested by the Mydlarz patents. Accordingly, Applicants submit that claims 1 and 4 and the claims dependent on those claims are not obvious over the cited art.

AMENDMENT UNDER 37 C.F.R. § 1.114(c) U.S. Application No. 10/642,583

Attorney Docket No. Q76907

Further, Applicants note that independent claims 4 and 9 recite a localized silver

iodochloride phase, while Edwards is directed to a localized silver bromide phase. Accordingly,

Applicants submit that the cited art does not teach or suggest the invention as recited in

independent claims 4 and 9 and the claims dependent on those claims.

Thus, Applicants submit that the present invention is not obvious over the cited art, and

withdrawal of this rejection is respectfully requested.

Conclusion

In view of the above, reconsideration and allowance of this application are now believed

to be in order, and such actions are hereby solicited. If any points remain in issue which the

Examiner feels may be best resolved through a personal or telephone interview, the Examiner is

kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 33,725

Bruce E. Kramer

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 7, 2006

6